Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial

Antiviral Therapy

Volumn 7, Issue 3, 2002, Pages 211-218

  Calvez, Vincent ^a   Costagliola, Dominique ^b   Descamps, Diane ^c   Yvon, Anne ^a   Collin, Gilles ^c   Cécile, Agnès ^a   Delaugerre, Constance ^a   Damond, Florence ^b   Marcelin, Anne Geneviève ^a   Matheron, Sophie ^b   Simon, Anne ^a   Valantin, Marc Antoine ^a   Katlama, Christine ^a   Brun Vézinet, Françoise ^c  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; LAMIVUDINE; NUCLEOSIDE ANALOG; STAVUDINE; THYMIDINE DERIVATIVE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CORRELATION COEFFICIENT; CROSS RESISTANCE; DRUG EFFICACY; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; MALE; MONONUCLEAR CELL; MULTIVARIATE ANALYSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; VIROLOGY; VIRUS MUTATION;

EID: 0036768696     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.1177/135965350200700301     Document Type: Article

References (23)

1. Katlama C, Valantin MA, Matheron S, Coutellier A, Calvez V, Descamps D, Longuet C, Bonmarchand M, Tubiana R, De Sa M, Lancar R, Agut H, Brun-Vezinet F & Costagliola D. Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infection. Annals of Internal Medicine 1998; 129:525-531.
2. Kline MW, Fletcher CV, Harris AT, Evans KD, Brundage RC, Remmel RP, Calles NR, Kirkpatrick SB & Simon C. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus. Journal of Pediatrics 1998; 132:543-546.
3. Lin PF, Gonzales CJ, Griffith B, Friedland G, Calvez V, Ferchal F, Schinazi RF, Shepp DH, Ashraf AB, Wainberg MA, Soriano V, Mellors JW & Colonno RJ. Stavudine resistance: an update on susceptibility following prolonged therapy. Antiviral Therapy 1999; 4:21-28.
4. Lin PF, Samanta H, Rose RE, Patick AK, Trimble J, Bechtold CM, Revie DR, Khan NC, Federici ME, Li H, Anderson RE & Colonno R. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. Journal of Infectious Diseases 1994; 170:1157-1164.
5. Prusoff W, Lin TS, Pivazyan A, Sun AS & Birks E. Empirical and rational approaches for development of inhibitors of the human immunodeficiency virus - HIV-1. Pharmacological Therapy 1993; 60:315-329.
6. Schinazi R, Larder B & Mellors J. Mutations in retroviral genes associated with drug resistance: 1999-2000 update. International Antiviral News 1999; 7:46-69.
7. Deminie CA, Bechtold CM, Riccardi K, Rose RE, Samanta H, Lin PF & Colonno RJ. Clinical HIV-1 isolates remain sensitive to stavudine following prolonged therapy [letter]. AIDS 1998; 12:110-112.
8. Soriano V, Dietrich U, Villalba N, Immelmann A, Gil-Aguado A, Echevarria S, Clotet B, Ocana I, Santamaria JM, Bouza E, Barona V, Gatell JM & Gonzalez-Lahoz J. Lack of emergence of genotypic resistance to stavudine after 2 years of monotherapy [letter]. AIDS 1997; 11:696-697.
9. Lacey SF & Larder BA. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2′,3′-didehyc1ro-2′,3′-dideoxythymidine in cell culture. Antimicrobial Agents and Chemotherapy 1994; 38:1428-1432.
10. Kavlick MF, Wyvill K, Yarchoan R & Mitsuya H. Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy. Journal of Infectious Diseases 1998; 177:1506-1513.
11. Shafer RW, Kozal MJ, Winters MA, Iversen AK, Katzenstein DA, Ragni MV, Meyer WAR, Gupta P, Rasheed S, Coombs R, Katzman M, Fiscus S & Merigan T. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. Journal of Infectious Diseases 1994; 169:722-729.
12. Shirasaka T, Kavlick MF, Ueno T, Gao WY, Kojima E, Alcaide ML, Chokekijchai S, Roy, E. Arnold BM, Yarchoan R & Mitsuya H. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxvnucleosides. Proceedings of the National Academy of Sciences USA 1995; 92:2398-2402.
13. Izopet J, Bicart-See A, Pasquier C, Sandres K, Bonnet E, Marchou B, Puel J & Massip P. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine. Journal of Medical Virology 1999; 59:507-511.
14. Brun-Vezinet F, Ingrand D, Deforges L, Gochi K, Ferchal F, Schmitt MP, Jung M, Masquelier B, Aubert J, Buffet-Janvresse C & Huraux JM. HIV-1 sensitivity to zidovudine: a consensus culture technique validated bv genotypic analysis of the reverse transcriptase. Journal of Virological Methods 1992; 37:177-188.
15. Galasso G, Whitley R & Merigan T (Editors). Antiviral Agents and Human Viral Diseases. 1997. Philadelphia: Lippincott-Raven.
16. Kellam P, Boucher CA & Larder BA. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proceedings of the National Academy of Sciences USA 1992; 89:1934-1938.
17. Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, Danner SA, Mulder J, Loveday C, Christopherson C, Kwok C, Sninsky J & Boucher CAB. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). Journal of Infectious Diseases 1995; 171:1411-1419.
18. Coakley EP, Gillis JM & Hammer SM. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS 2000; 14:F9-15.
19. Pellegrin I, Izopet J, Reynes J, Denayrolles M, Montes B, Pellegrin JL, Massip P, Puel J, Fleury H & Segondy M. Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. STADI Group. AIDS 1999; 13:1705-1709.
20. Picard V, Angelini E, Maillard A, Race E, Clavel F, Chene G, Ferchal F & Molina JM. Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine. Journal of Infectious Diseases 2001; 184:781-784.
21. Johnson V, Bassett R, Koel J, Rhodes R, Young R, Barett H & Kuritzkes D. Selection of zidovudine resistance mutations by zidovudine or stavudine-based regimens and relationship to subsequent virological response in ACTG 370. 4th International Workshop on HIV Drug Resistance and Treatment Strategies, Sitges, Spain, 12-16 June 2000; Abstract 57.
22. Mouroux M, Descamps D, Izopet J, Yvon A, Delaugerre C, Matheron S, Coutellier A, Valantin MA, Bonmarchand M, Agut H, Massip P, Costagliola D, Katlama C, Brun-Vézinet F & Calvez V. Low-rate emergence of thymidine analogue mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy. Antiviral Therapy 2001; 6(3):179-183.
23. Duan C, Poticha D, Stoeckli T, Petroupuolos C, Whitcomb J, McHenry C & Kuritzkes D. Biochemichal evidence of cross-resistance to stavudine triphosphate in purified HIV-1 reverse transcriptase derived from a zidovudine-resistance isolate. 4th International Workshop on HIV Drug Resistance and Treatment Strategies, Sitges, Spain, 12-16 June 2000; Abstract 55.